APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma-Reference-Cited by-同舟云学术

APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma

Published:2015-07-17 Issue:10 Volume:64 Page:1506-1516
ISSN:0017-5749
Container-title:Gut
language:en
Short-container-title:Gut

Author:

Liu David S H,Read Matthew,Cullinane Carleen,Azar Walid J,Fennell Christina M,Montgomery Karen G,Haupt Sue,Haupt Ygal,Wiman Klas G,Duong Cuong P,Clemons Nicholas J,Phillips Wayne A

Publisher

BMJ

Subject

Gastroenterology

Reference37 articles.

1. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends;Thrift;Ann Oncol,2012

2. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis;Sjoquist;Lancet Oncol,2011

3. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity;Dulak;Nat Genet,2013

4. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis;Weaver;Nat Genet,2014

5. p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus;Yamasaki;Ann Surg Oncol,2010

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HER2 Amplification and PD-L1 Expression in Advanced Gastric Cancer: Correlations, Clinical Implications, and Molecular Characteristics;2024-08-19

2. Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within interleukin-6 family cytokines;Cell Reports;2024-08

3. APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy;Cell Death & Disease;2024-06-18

4. Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within Interleukin-6 family cytokines;2024-04-26

5. p53 biology and reactivation for improved therapy in MDS and AML;Biomarker Research;2024-03-13